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Abstract Breast cancers are categorized into three sub-
types based on protein expression of estrogen receptor
(ER), progesterone receptor (PR), and human epidermal
growth factor receptor-2 (HER2/ERBB2). Patients enroll
onto experimental clinical trials based on ER, PR, and
HER2 status and, as receptor status is prognostic and
defines treatment regimens, central receptor confirmation is
critical for interpreting results from these trials. Patients
enrolling onto experimental clinical trials in the metastatic
setting often have limited available archival tissue that
might better be used for comprehensive molecular profiling
rather than slide-intensive reconfirmation of receptor sta-
tus. We developed a Random Forests-based algorithm
using a training set of 158 samples with centrally con-
firmed IHC status, and subsequently validated this algo-
rithm on multiple test sets with known, locally determined
IHC status. We observed a strong correlation between
target mRNA expression and IHC assays for HER2 and
ER, achieving an overall accuracy of 97 and 96 %,
respectively. For determining PR status, which had the
highest discordance between central and local IHC,
incorporation of expression of co-regulated genes in a
multivariate approach added predictive value, outper-
forming the single, target gene approach by a 10 % margin
in overall accuracy. Our results suggest that multiplexed
qRT-PCR profiling of ESR1, PGR, and ERBB2 mRNA,
along with several other subtype associated genes, can
effectively confirm breast cancer subtype, thereby con-
serving tumor sections and enabling additional biomarker
data to be obtained from patients enrolled onto experi-
mental clinical trials.
Keywords Breast cancer  Receptor concordance  ER 
PR  HER2  Random forest  IHC  Biomarkers  qPCR
Introduction
Breast cancer is a heterogeneous disease that is routinely
categorized by immunohistochemical (IHC) staining of
estrogen receptor (ER), progesterone receptor (PR), and the
human epidermal growth factor receptor-2 (HER2) [1].
Hormone receptor positive cancers stain positive for either
ER or PR and are generally treated with anti-hormone
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therapies such as tamoxifen and letrozole [2]. HER2 positive
breast cancers overexpress the HER2/neu oncogene and are
treated with HER2-directed therapies, such as trastuzumab,
lapatinib, pertuzumab, and trastuzumab emtansine, which
have improved outcomes and changed the natural history of
this previously poor prognostic patient subgroup [3]. Triple
negative breast cancers (TNBC) lack ER, PR, and HER2
staining and currently have no approved targeted therapies.
TNBC is generally treated with combinations of cytotoxic
agents such as anthracyclines and taxanes [4].
Over a decade ago, Perou and others provided evidence
that breast cancer could be divided molecularly into distinct
subgroups based on RNA microarray experiments [5–8].
Follow-up studies demonstrated that a 50-gene signature
(subsequently designated the PAM50) could recapitulate the
initial studies by Perou and colleagues [9]. Using this assay,
breast cancer can be stratified into luminal A and luminal B
subgroups that mostly comprise hormone receptor positive
breast cancers; basal-like subgroup that mostly comprises
triple negative breast cancers; HER2-enriched subgroup that
mostly comprises HER2? breast cancers, and a normal-like
subgroup that has been proposed to mostly comprise the
normal surrounding stroma [10]. PAM50 analysis has been
shown to provide independent prognostic information
compared to standard IHC classification. However, the
PAM50 intrinsic subtypes show imperfect agreement with
IHC classification, not surprisingly since they were designed
to provide additional orthogonal information [11], sug-
gesting that predictors that can recapitulate IHC status may
still have independent clinical utility in the context of cur-
rently approved therapies.
Specifically, despite the promise of molecular assays
such as PAM50 and other classifiers, patients are still
treated and routinely enrolled onto clinical trials of
experimental anti-cancer agents based on IHC determina-
tion of ER, PR, and HER2. Such testing requires at least
three tissue sections, and often more if staining needs to be
repeated. Moreover, if HER2 status is deemed equivocal
(i.e., 2?), additional testing is required using a fluores-
cence in situ hybridization (FISH) assay [12]. Moreover,
IHC is subject to variation in inter-pathologist interpreta-
tion, and as such, concordance between laboratories can
vary. In several studies, discordant results were noted
between IHC staining between local and central assess-
ment. In a study by Martinez and colleagues, ER showed a
concordance rate of 92 %, PR showed a concordance rate
of 78 %, and HER2 showed a concordance rate of 83 %
[13]. In a similar study, Orlando et al. demonstrated con-
cordance rates of 82 % for ER, 86 % for PR, and 73 % for
HER2 [14]. Based on these considerations, a facile method
of subtype assignment that uses minimal slides and shows
high concordance with central IHC testing would be highly
desirable from a clinical biomarker perspective.
Patients enrolled in experimental clinical trials are often
late line metastatic patients who may have undergone
multiple rounds of diagnostic testing and often have limited
tissue remaining. Comprehensive biomarker profiling of
study-enrolled patients is thus challenging and could ben-
efit from multiplexed technologies rather than more tradi-
tional individual slide-based assays. In this study, we
showed that ER, PR, and HER2 status could be accurately
confirmed using multiplexed RNA expression profiling,
thereby conserving tissue sections and maximizing the
value of limited tissue samples from clinical trial patients.
Results
Comparison of local and central IHC testing for ER,
PR, and HER2 status
As ER, PR, and HER2 status is typically determined by
different pathologists in various institutions (local testing)
and is subject to inter-observer variability, we re-analyzed
the expression of ER, PR, and HER2 using a single
pathologist (central testing) from 158 patients enrolled in
the United States Oncology (USO) phase III study 01062
(USO 01062), which tested the addition of capecitabine to
standard adjuvant therapy in high-risk breast cancer [15].
Receptor positivity, here and throughout the manuscript, is
defined as an IHC3? score for HER2 and an Allred cutoff
of 3 and above for ER and PR. In general, a strong con-
cordance was observed between local and central testing
for ER, PR, and HER2 status (Table 1: 92, 84 and 94 %
accuracy, respectively), which is similar to previously
published studies [13, 14]. However, when breaking down
concordances into positive predictive values (PPV) and
negative predictive values (NPV), discrepancies were high
for certain subgroups of patients. Specifically, a low PPV
of local testing was observed in the HER2? subgroup of
patients. Only 16 of 24 samples positive by local testing
were confirmed by central testing (PPV = 67 %), although
132 of 134 samples negative by local testing were negative
by central testing (NPV = 99 %). Similarly for PR testing,
a low NPV was observed for local testing of PR negative
patients (NPV = 68 %), with only 50 of the 73 negative
samples by local testing confirmed by central testing.
Generation of a training set to develop the predictive
algorithm for ER, PR, and HER2 status
Receptor status is critical for enrollment and stratification
of breast cancer patients onto clinical trials, therefore we
sought to determine whether a molecular classifier could
accurately predict molecular subtype with the benefit of
obtaining additional valuable biomarker data that ER, PR,
316 Breast Cancer Res Treat (2014) 148:315–325
123
and HER2 IHC assays would not capture. Using the 158
IHC centrally confirmed patient samples, we extracted
RNA and profiled the samples using a previously reported
96-gene BioMarkTM Fluidigm microfluidics quantitative
RT-PCR-based platform that was developed to capture
expression of breast cancer genes involved in proliferation
and various aspects of breast cancer signaling [16].
Several studies have shown that mRNA expression of
the three receptors correlates with IHC assays for the
corresponding protein expression [11, 17]. Similarly, we
observed a strong correlation between the centrally con-
firmed IHC status of ER, PR, and HER2 and their corre-
sponding target gene expression, ESR1, PGR, and ERBB2
(Fig. 1 and Supplemental Fig. 1, N = 158). Pearson cor-
relation coefficients of IHC and target gene expression
were 0.91, 0.80, and 0.60 for ER, PR, and HER2, respec-
tively. In a receiver operating characteristic (ROC) ana-
lysis, the area under the curve (AUC) for predicting HER2
IHC3? samples using ERBB2 expression was 0.998
(Fig. 1a). To confirm that ERBB2 qRT-PCR data could
accurately determine HER2 status, we developed a DNA-
based HER2 copy number assay that showed a high cor-
relation with ERBB2 gene expression that more accurately
captured the HER2 amplified cases based on central con-
firmation (Supplemental Fig. 2). Notably, three of the cases
that were HER2 IHC positive by local but not central
testing clustered with the IHC negatives when assessed
using this methodology.
For the determination of ER and PR status, we utilized
the Allred scoring criteria for positivity [18, 19] and
applied ROC analysis to examine the positive predictability
defined by different Allred score cutoffs using RNA
expression level. For ER and PR status, an AUC of 0.98
and 0.90, respectively, was observed at the FDA-recom-
mended Allred cutoff of 3 and above (Fig. 1b, c).
Performance of target gene prediction
Encouraged by the strong RNA IHC correlations observed
for the three target genes (Fig. 1) and to formally address
the question whether mRNA target expression can be used
to determine central IHC status reliably in a statistical
framework, we applied a two-component Gaussian mixture
model approach to the empirical distributions of ERBB2,
ESR1, and PGR expression, motivated by the bimodal
marginal distribution of these genes (Fig. 2). A cutoff point
between high and low expression was selected at the value
where the posterior probabilities for the two components
were equal. For the determination of HER2, ER, and PR
status, this target gene prediction (TGP) approach achieved
an overall accuracy of 97, 96, and 81 %, respectively
(Table 2). Although PR status determination remained
challenging by TGP, there was a pronounced improvement
in determining HER2 and ER status by TGP compared to
local IHC. The PPV of HER2, which was 67 % for local
testing was increased to 100 % for TGP. This high con-
cordance between TGP and central IHC status, especially
in the HER2 and ER groups, suggests that the PCR-based
assay is a reliable surrogate for central IHC to confirm
receptor status.
Performance of multivariate gene prediction
To investigate whether incorporating information from other
genes in addition to target genes in the BioMarkTM panel will
further improve the prediction performance, especially in
predicting the more challenging PR status, we applied and
contrasted several multivariate classifiers. These include
Random Forests (RF) [20], prediction analysis of micro-
arrays (PAM) [21], and a Random Forests and K-Nearest
Neighbors combination approach (RF-KNN), which utilizes
RF for variable selection and KNN for formalizing predic-
tion (see ‘‘Materials and methods’’ section and Table 3).
Both RF-based approaches performed better than PAM, and
achieved an overall cross-validated accuracy of 98, 95, and
91 % for HER2, ER, and PR status prediction. Variable
importance measures (VIM) produced by RF were elicited to
quantify the relative importance of genes in contributing to
prediction accuracy (Fig. 3). For HER2 status prediction, the
genes that predicted this group were ERBB2 and GRB7,
which is often co-amplified with ERBB2 [22], with a sensi-
tivity and specificity of 83 and 100 %, respectively
(Table 3). For ER status prediction, the gene with the highest
VIM and was most often selected by RF-KNN was ESR1,
Table 1 HER2, ER, and PR status by local and central IHC for 158 USO 01062 study Samples
HER2 Central IHC ER Central IHC PR Central IHC
- ? - ? - ?
Local IHC Local IHC Local IHC
- 132 2 NPV 99 % - 50 8 NPV 86 % - 50 23 NPV 68 %
? 8 16 PPV 67 % ? 4 96 PPV 96 % ? 3 82 PPV 96 %
Spec 94 % Sens 88 % Acc 94 % Spec 93 % Sens 92 % Acc 92 % Spec 94 % Sens 78 % Acc 84 %
Spec specificity, Sens sensitivity, PPV positive predictive value, NPV negative predictive value, Acc accuracy
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followed by known ER-regulated genes, such as GATA3,
PGR, SCUBE2, and FOXA1 [7, 23–25], with a sensitivity
and specificity of 93 and 98 %, respectively. For PR status
prediction, the most predictive gene was ESR1, followed by
PGR and several other ER-regulated genes, with a sensitivity
and specificity of 90 and 92 %, respectively. Notably, using a
cutoff of Allred score of 4 and above for PR positivity
showed a stronger correlation with the expression level of
PGR (Fig. 1c and Supplemental Fig. 3; AUC = 0.96,
95 % CI 0.93–0.99), compared to the FDA-recommended
cutoff of 3 and above (AUC = 0.9, 95 % CI 0.86–0.95).
This superior AUC for Allred score of 4 and above is sup-
ported by a significant increase in PGR expression between
Allred scores 3 and 4 (t-test P = 0.003), and conversely, a
lack of change in PGR expression between Allred scores 2
and 3 (t-test P = 0.12).
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Fig. 1 Target gene expression
of a ERBB2 b ESR1 c PGR by
central IHC status. Left panel:
boxplot of target gene
expression by central HER2
status. IHC positive group is
colored in gray. Right panel:
ROC analysis for predicting
IHC positivity defined by
different cutoffs using target
gene expression. Figure legend
indicates cutoffs and AUCs with
95 % confidence intervals in
parentheses
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As the target genes were often the most predictive genes
for the determination of ER, PR, or HER2 status, we
contrasted the performance of Random Forests-based pre-
diction (RFP; Table 3) with the target gene prediction
approach (TGP; Table 2). Both approaches showed similar
overall accuracy in predicting central IHC score for HER2
and ER. In the case of PR prediction, RFP outperformed
the TGP approach based on PGR expression by a 10 %
margin in overall accuracy (91 vs. 81 %, respectively).
Taken together, these results suggest that inclusion of
additional target or co-regulated PGR genes in a multi-
variate approach has a greater predictive power in deter-
mining PR status than TGP.
Application of the ER, PR, and HER2 predictive
algorithm to test sets
To determine how the predictive algorithm performs in
different cohorts of patients, we applied RFP to three
separate breast cancer sample sets. First, we applied RFP to
an additional 630 patients enrolled onto the USO 01062
study where local ER, PR, and HER2 status was available.
The overall concordance between RFP and local IHC
testing for determining HER2, ER, and PR status was 92,
92, and 82 %, respectively (Table 4 and Supplemental
Table 1). Figure 4 shows the distribution of target genes
ERBB2, ESR1, and PGR categorized by the predicted and
the local IHC subtypes for ER, PR, and HER2. Similar to
the training set, lower concordance was observed between
local HER IHC and RFP within the subset of HER2?
patients determined by local IHC (Table 4). Among the 83
HER2? patients determined by local IHC, only 41 were
predicted to be positive by RFP, with the rest exhibiting
very low target gene ERBB2 expression levels (Fig. 4). To
examine whether this discrepancy has clinical implication,
we correlated local IHC and RFP with disease-free survival
in the USO 01062 study (Fig. 5). We defined HER2?
patients as those being HER2 positive regardless of ER or
PR status, HR? patients as those being HER2 negative and
either ER or PR positive, and TNBC patients as those being
HER2, ER, and PR negative. Significant survival disad-
vantages was observed for HER2? patients compared to
the HR? or TNBC patients by RFP subtyping (log-rank




















































Fig. 2 Target gene prediction. A bimodal, 2-component Gaussian
mixture distribution fit was superimposed to the actual data summa-
rized in the histogram. The two mixture distributions are depicted in
red and black lines. The dotted line indicates the cutoff between the
positive and negative groups
Table 2 HER2, ER, and PR status by central IHC and TGP for the training set
HER2 Central IHC ER Central IHC PR Central IHC
- ? - ? - ?
ERBB2 ESR1 PGR
- 139 4 NPV 97 % - 53 5 NPV 90 % - 39 16 NPV 71 %
? 0 14 PPV 100 % ? 1 99 PPV 99 % ? 14 89 PPV 86 %
Spec 100 % Sens 77 % Acc 97 % Spec 98 % Sens 95 % Acc 96 % Spec 74 % Sens 84 % Acc 81 %
Spec specificity, Sens sensitivity, PPV positive predictive value, NPV negative predictive value, Acc accuracy
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suggesting that some of the 83 HER2? patients by local
IHC were likely misclassified. Second, when the algorithm
was applied to a commercially procured sample set of 136
HR? breast cancers with locally determined ER status
[16], 129 were determined to be HR? with an overall
accuracy of 95 % (Supplemental Fig. 4 and Supplemental
Table 2). Among the seven samples that were predicted as
ER and PR negatives, two were a primary and metastatic
pair, exhibiting high ERBB2 expression. Finally, in a
commercially procured sample set of 37 locally assessed
triple negative breast cancers, 34 were determined to be
triple negative with an overall accuracy of 92 % (Supple-
mental Table 2). These results suggest that multiplexed
RNA assays can be leveraged to validate local IHC status,
obviating the need to centrally confirm IHC receptor status
for patients enrolled onto studies.
Discussion
In our current study, we demonstrated that multiplexed
PCR-based methods can accurately predict ER, PR, and
HER2 status in breast cancer patients when coupled with a
RF-based approach that takes into consideration multiple
genes that are associated with the unique biology of breast
cancer. Most notably, for predicting PR status, incorpora-
tion of PR target or co-regulated genes such as GATA3,
ESR1, and FOXA1 adds predictive benefit when compared
to PGR alone. In the USO 01062 training set that incor-
porated central IHC determination, the accuracy of
assigning breast cancer subtypes was much superior com-
pared to local testing. In our training set of 24 HER2?
samples locally assessed from the USO 01062 trial, 16
were positive by central staining. This large discordance,
Table 3 Performance of multivariate prediction methods for the training set
Accuracy Specificity Sensitivity Genes picked (number of times)
HER2
RF 0.98 1(140/140) 0.83(15/18)
RF-KNN 0.99 1(140/140) 0.94(17/18) ERBB2(10) GRB7(1)
PAM 0.94 1(140/140) 0.5(9/18)
ER
RF 0.95 0.98(53/54) 0.93(97/104)
RF-KNN 0.95 0.96(52/54) 0.94(98/104) ESR1(10) GATA3(8) TFF1(4) FOXA1(3)
SCUBE2(3) PGR(2) LYN(1) VAV3(1)
PAM 0.95 0.94(51/54) 0.95(99/104)
PR
RF 0.91 0.92(49/53) 0.90(95/105)
RF-KNN 0.91 0.91(48/53) 0.91(96/105) ESR1(10) GATA3(7) PGR(7) FOXA1(6) SCUBE2(6)
TFF1(6) IGF1R(3) BCL2(2) BUB1(2)
XBP1(2) CTSL2(1) ERBB3(1) IRS1(1)
PAM 0.91 0.91(48/53) 0.90(95/105)
Fig. 3 Multivariate variable importance measures (VIM) by RF for
HER2, ER, and PR prediction. Y axes are –log10 based P values of
the two group t-test between central IHC positive and negative
groups, and (Bonferroni) adjusted P value 0.05 is marked with gray
lines. Genes with two sample t-test adjusted P values B0.05 and fold
change C2 were marked with gene symbols
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Table 4 HER2, ER and PR status by local IHC and RFP for test set 1, an additional set of USO 01062 study samples
HER2 Local IHC ER Local IHC PR Local IHC
- ? - ? - ?
RFP RFP RFP
- 538 42 NPV 93 % - 249 20 NPV 93 % - 246 21 NPV 92 %
? 7 41 PPV 85 % ? 28 337 PPV 92 % ? 94 273 PPV 74 %
Spec 99 % Sens 49 % Acc 92 % Spec 90 % Sens 94 % Acc 92 % Spec 72 % Sens 93 % Acc 82 %
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Fig. 4 Boxplots of ERBB2, ESR1, and PGR mRNA by local IHC and
RFP results for test set 1, an additional set of USO 01062 study
samples with local IHC status. Black points are local IHC and RFP
negatives, red points are local IHC positives and RFP negatives,
green points represent local IHC negatives and RFP positives, and
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Fig. 5 Kaplan–Meier curves
showing disease-free survival
for disease subtypes by local
IHC (a) and RFP (b)
Breast Cancer Res Treat (2014) 148:315–325 321
123
even utilizing similar methodologies, may perhaps explain
the lack of concordance between HER2 IHC local
determination and our HER2 RFP algorithm in the ana-
lysis of the larger test set. Similarly, a high degree of
discordance between HER2 status between local and
central/reference sites has been shown in independent
studies, ranging from 13 to 26.6 % [13, 14]. Of note, we
found significant survival differences in the HER2 posi-
tive group between those patients classified by IHC or
RFP, an observation that was not observed in the HR? or
TNBC groups. This poorer disease-free survival observed
with the HER2 RFP is more consistent with the literature
suggesting a negative prognostic impact of HER2 status
prior to the approval of trastuzumab-containing regimens,
with only approximately 30 % of the HER2 positive
patients receiving trastuzumab-based therapies following
completion of the experimental adjuvant therapy [6]. A
similar gene expression analysis was carried out by Prat
et al. in HER2 IHC positive breast cancer patients treated
with a trastuzumab-containing regimen, in which the
HER2-enriched group, as defined by PAM50, derived a
significant survival benefit compared to the group defined
as non-HER2-enriched [26].
Molecular subtyping using PAM50 is not an effective
surrogate for IHC status since it identifies distinct sub-
types (luminal A, luminal B, basal-like, and HER2-enri-
ched) with different prognostic implications [9]. In a
similar study assessing ESR1, PGR, and ERBB2 gene
expression using quantitative RT-PCR, Du, and col-
leagues determined that single gene expression had a
concordance rate of 87 % within the luminal subtype,
75 % within the HER2? subtype, and 48 % within the
triple negative subtype [17]. Of the 52 % discordant cases
in the triple negative subtype, 12 out of the 17 (71 %)
cases were determined to be luminal by RNA expression.
The authors demonstrate the prognostic differences
between the three IHC subtypes, with the luminal sub-
group being the more favorable group followed by the
triple negative and then HER2? group. Interestingly, by
RT-PCR subtyping, the HER2? and triple negative sub-
groups had reversed prognostic trend, although, this may
have been driven by the small HER2? patient population
in this sample set, comprising of only 9 cases. In a second
study, Haibe-Kains et al., suggested that the simplest
three gene classification model, SCMGENE, which com-
prised ESR1, PGR, and AURKA was largely concordant
with other more complex gene expression models in terms
of subtype prediction [27]. In addition, the authors show
that their SCMGENE model demonstrated similar prog-
nostic implications when compared to more established
models such as PAM50, MAMMAPRINT, and ONCO-
TYPE gene expression signatures, and may be adequate
for clinical management of patients. Comparing RT-PCR
methods to IHC, Bastien et al. demonstrated an AUC,
sensitivity, and specificity for ER to be 0.90, 0.96, and
0.74, respectively; PR to be 0.90, 0.84, and 0.85,
respectively; and HER2 to be 0.95, 0.94, and 0.85,
respectively [11]. When the authors compared the prog-
nostic differences between the different methodologies,
the ER?/ESR1? and ER-/ESR1? subgroups had similar
clinical outcomes, and performed better than patients who
were ER-/ESR1- or ER?/ESR1-, suggesting that RT-
PCR assignment of ESR1 status was more prognostic and
accurate than IHC for ER [11]. This observation may be
driven by the ability of RT-PCR technologies to accu-
rately detect low percentage ER? cells within the tumor
population. As such, tumors that have ER IHC expres-
sion 1–9 % have a worse prognosis compared to tumors
that have an ER IHC expression of 10 % or greater [28],
which may, in part, explain the results of Bastien and
colleagues. Interestingly, we observed notable differences
in the RFP for PR predicted genes based on the Allred
cutoff. Using an Allred cutoff of 3, ESR1 was the gene
that best predicted PR IHC status. However, with the
cutoff extended to 4, PGR became the most predictive
gene. These results suggest that extending the Allred
score to 4 for a positive PR result may more accurately
predict PR status, an observation that warrants further
clinical investigation.
In conclusion, central confirmation of breast cancer
receptor status is critical for the interpretation of clinical
data from experimental trials. Our study suggests that
local and central testing show substantial overall con-
cordance, but that a PCR-based classifier offers a rea-
sonable strategy to identify the set of samples that may
have been erroneously classified and subject them to
further testing. Such an approach has added valued in
that it conserves 3–5 slides that would be used for repeat
IHC testing, and also yields expression data on up to 90
breast cancer-related genes. As tissue can be limited in
patients who have gone through multiple lines of therapy
in the metastatic setting, multiplexed assays provide an
attractive method of obtaining valuable biomarker data
for association with clinical outcomes. We proposed two
RF-based approaches, RF and RF-KNN. While both
approaches performed similarly, the former classifier
requires the usage of the same 96 genes for test samples,
and the latter, through implementing a preliminary fea-
ture selection step, relies on a smaller set of genes for
prediction, providing flexibility in panel development. In
the current report, we demonstrate the utility of PCR-
based multiplexed assays to accurately confirm ER, PR,
and HER2 status and obviate the need for central IHC
confirmation of subtype, while obtaining additional bio-
marker data on a diverse set of breast cancer-related
genes.




Formalin-fixed paraffin-embedded (FFPE) tumor samples
were obtained from (n = 158 ? 630) breast cancer
patients as part of a completed phase III study (‘‘A Ran-
domized, Open-Label, Multicenter, Phase Ill Trial Com-
paring Regimens of Adriamycin plus Cytoxan Followed by
Either Taxotere or Taxotere plus Xeloda as Adjuvant
Therapy for Female Patients with High-Risk Breast Can-
cer’’) (http://clinicaltrials.gov/show/NCT00089479). Tis-
sue samples were collected and analyzed following
approval by the US Oncology, Inc. Institutional Review
Board and appropriate confirmation of written informed
consent. ER, PR, and HER2 status was determined by local
testing.
Breast cancer tumor blocks were procured for 173
breast cancer tumors. Tissue samples were obtained from
Cureline, Inc (South San Francisco, CA) following
approval of the Ethics Committee of Saint Petersburg City
Clinical Oncology Hospital and appropriate confirmation
of written informed consent. Tissue samples were also
obtained from The MT Group (Van Nuys, CA) following
IRB approval (http://www.sterlingirb.com). The IRB
waived the need for written informed consent per FDA
guidelines, as this was a retrospective study with anony-
mized patient data. ER, PR, and HER2 status was deter-
mined by local testing.
Gene expression
Hematoxylin–eosin sections were prepared for all samples
and were reviewed by a pathologist to confirm diagnosis
and assess tumor content. RNA extraction and gene
expression analysis were performed as previously descri-
bed [16]. Briefly, FFPE sections were macrodissected to
enrich for neoplastic tissue followed by RNA extraction
using the High Pure FFPE RNA Micro Kit (Roche
Applied Sciences, Indianapolis, IN). RNA was then sub-
jected to a one-step cDNA synthesis/preamplification
reaction using the Invitrogen Platinum Taq/Reverse
Transcriptase enzyme mix and pooled TaqMan Gene
Expression Assays (Life Technologies, Carlsbad, CA).
Quantitative PCR (qPCR) was then conducted on Flui-
digm 96.96 Dynamic Arrays using the BioMarkTM HD
system (Fluidigm Corporation, South San Francisco, CA).
Cycle threshold (Ct) values were normalized and con-
verted to relative expression values (negative delta Ct) by
subtracting the median gene expression estimated using
all 96 genes on the array.
Immunohistochemical staining
A total of 158 samples from the phase III trial (24 HER2? ,
43 ER-/PR-/HER2-, and 91 ER and/or PR?/HER2-
based on local testing) were chosen at random and centrally
confirmed for ER, PR, and HER2. Antibodies for ER
(SP1), PR (1E2), and HER2 (4B5) were obtained from
Ventana Medical Systems, Inc., (Tucson, AZ). IHC was
performed using the Discovery XT (ER, PR) or Bench-
Mark XT (HER2) systems (Ventana). All samples were
scored by a single pathologist (E.F.). Standard guidelines
for HER2 protein overexpression assessment were used;
samples were scored as 0, 1, 2, or 3, where a score of 0 and
1 are considered negative for HER2 protein overexpres-
sion, 2 is weakly positive and equivocal, and 3 is strongly
positive. For ER and PR assessment, the Allred score was
calculated by adding the proportion score (PS) with the
intensity score (IS). The PS scores are as follows: 0 = no
staining, 1 C 0–1 %, 2 C 1–10 %, 3 C 10–33 %,
4 C 33–67 %, 5 C 67–100 % cells stained. IS scores are
as follows: 0 = no intensity, 1 = weak, 2 = intermediate,
and 3 = strong. Interpretation is positive or negative based
on total score (PS ? IS) where total score of 0, 1 or 2 is
negative and a score of 3 or greater is positive.
Target gene prediction algorithm
A two-component Gaussian mixture model was applied to
the empirical ERBB2, ESR1, and PGR expression data, and
model fitting made recourse to the R library mclust [29].
Posterior conditional probabilities of the component mem-
bership for each sample were computed using the fitted
parameters, and a threshold of C0.5 was used to classify a
sample as having positive expression of the receptor.
Multivariate prediction algorithm
We applied and contrasted the following multivariate
classification algorithms to predict HER2, ER, and PR IHC
positivity separately. Both PAM and RF are often used for
high-dimensional data settings where the number of vari-
ables exceeds the number of observations.
PAM
The nearest shrunken centroid method (also called PAM
[21]) was applied to normalized gene expression of 158
samples from the USO 01062 trial with central IHC status.
Prediction performance was valuated using 10-fold cross
validation. The application of the PAM algorithm utilized
the R library pamr.
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Random Forests
The RF classification was performed using the random-
Forest library in R. Forests were created with 10,000 trees
and default settings. Advantages of the RF method include
its ability to handle a large number of variables, provide
variable importance measures (VIM), and produce accurate
and unbiased estimates of prediction performance without
the utilization of a separate test set. The VIM from RF we
used is the mean decrease in accuracy generated by this
predictor whenever it was selected for splitting, compared
to when the values for the predictor was permuted.
Random Forests ? KNN
The hybrid approach combining RF and KNN (K-nearest
neighbors, K = 3) utilizes RF for variable selection and
KNN for formalizing prediction based on RF-selected
variables. This procedure was carried out using 10-fold
cross validation. Briefly, (i) the whole dataset was ran-
domly subdivided into 10 subsets, 9 of which were used to
construct an RF predictor. (ii) Variables were ordered by
VIM and the N variables that were at least 1/10 of the
highest VIM were selected. (iii) To select the smallest
possible set of genes for minimal misclassification error
rate, out-of-bag error rates using the N RF classifiers
sequentially fitted using the top M (M = 1,…,N) variables
were obtained and contrasted. The set of variables
(assuming size is P (1 B P B N)) variables that had lowest
out-of-bag error rate were selected. (iv) A classifier was
then built using KNN (K = 3) and the P variables, and its
unbiased prediction error was obtained by predicting the
left-out subset from the whole dataset. (v) This process was
repeated for each left-out fold. The frequency of genes
picked within each fold was recorded.
ERBB2 copy number estimation by real-time
quantitative PCR
FFPE tumor DNA was prepared by QIAamp DNA FFPE
Tissue Kit from macrodissected tumor sections as previous
described [16]. Genomic FFPE DNA (200 ng) was then
subjected to 17 cycles of preamplification using pooled
gene specific primers at 50 nM each and TaqMan Pre-
amplification Master Mix (Life Technologies) according to
the manufacture protocol. The preamplified samples were
diluted 5 fold and qPCR was performed using Fluidigm
96.96 Dynamic Arrays on the BioMarkTM system accord-
ing to the manufacture instruction. In brief, sample mix
contains DNA, TaqMan Gene Expression Master Mix
(Life Technologies), DNA binding sample loading reagent
(Fluidigm) and EvaGreen dye (Biotium, Hayward, CA).
Assay mix contains gene specific primer pairs and sample
loading reagent (Fluidigm). The Ct determination and melt
curve analyses were carried out by Fluidigm Gene Analysis
Software. Relative gene copy numbers of ERBB2 were
calculated by the Delta Delta Ct method as described
previously [30]. Reference genes used for Delta Ct calcu-
lation were RPPH1, GPG15 and ZNF80 and median of
Delta Ct from each gene was used as a calibrator for Delta
Delta Ct calculation. Primers used were: ERBB2_1F 50-GC
AGTTACCAGTGCCAATATCC-30 and ERBB2_1R 50-AT
CAAAGCTCTCCGGCAGAA-30; ERBB2-_2F 50-CTG
GTCACCTACAACACAGACA-30 and ERBB2_2R 50-AG
CTGGCGCCGAATGTATA-30; RPPH1_1F 50-GCCAGCG
AAGTGAGTTCAA-30 and RPPH1_1R 50-GCGGAGGAG
AGTAGTCTGAA-30; RPPH1_2F 50-GCCAGC GAAGTG
AGTTCAA-30 and RPPH1_2R 50-GCGGAGGAGAGTAG
TCTGAA-30; GPR15_F 50-CCCTTTGTTGACAT TGTG
ACCTG-30 and GPR15_R 50-TGGTAATGGGCACACAG
CTTCCTT-30; ZNF80_F 50-CAGCTCATCCTCACTT GG
CATTGA-30 and ZNF80_R 50-GGCCTTCCCACATATC
TCATAGAGT-30.
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